Moxifloxacina Oara

Moxifloxacin, the active ingredient in Moxifloxacina Oara, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a range of bacterial infections in adult patients, including respiratory and skin infections. GNH USA supplies Moxifloxacina Oara as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxifloxacina Oara is a fluoroquinolone antibiotic used to treat bacterial infections in the respiratory and skin pathways. - Community‑acquired bacterial pneumonia: eradicates the causative pathogens and improves lung function. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection. - Acute bacterial exacerbation of chronic bronchitis: shortens symptom duration and prevents complications. - Complicated skin and skin‑structure infections: eliminates bacterial load and promotes wound healing.

Moxifloxacina Oara may cause adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, often self‑limiting. - Headache: transient cranial discomfort. - Dizziness: occasional sense of imbalance. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Tendon rupture: sudden pain and loss of function, especially in the Achilles. - QT interval prolongation: potential cardiac arrhythmia. - Severe hypersensitivity: anaphylaxis or Stevens‑Johnson syndrome. - Clostridioides difficile colitis: severe diarrhea with abdominal pain. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before prescribing Moxifloxacina Oara, clinicians should consider several safety aspects. - Tendon health: avoid use in patients with recent tendon injury or corticosteroid therapy. - Cardiac risk: assess QT prolongation potential in patients with known arrhythmias. - Renal function: adjust monitoring in severe renal impairment. - Pregnancy and lactation: use only if benefits outweigh potential risks, as safety data are limited. - Drug hypersensitivity: discontinue if signs of severe allergic reaction appear. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Moxifloxacina Oara can affect or be affected by other medicines, requiring careful review.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of moxifloxacin. - Warfarin: may increase anticoagulant effect and bleeding risk. - Drugs that prolong QT interval (e.g., quinidine, haloperidol): heighten arrhythmia risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of central nervous system stimulation. - Corticosteroids: combined use may raise tendon rupture risk. - Theophylline: may elevate plasma concentrations, requiring dose adjustment.